Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Next Previous
Trial Profile

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voclosporin (Primary) ; Mycophenolate; Steroids
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AURORA 1
  • Sponsors Aurinia Pharmaceuticals

    • Most Recent Events

    • 01 Mar 2024 Results of subgroup analysis examining the efficacy and safety of voclosporin in patients with proliferative lupus nephritis and high levels of proteinuria published in the Clinical Journal of The American Society of Nephrology: CJASN
    • 15 Nov 2023 Results assessing to compare and analyze the safety and efficacy data in propensity-matched patients from the ALMS (n=96) and AURORA 1 (n=96), presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results from the AURORA 1 and AURORA 2 assessing Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis, presented at the ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top